Abstract
Introduction

32
For a long time, the treatment of most infections in western countries has been considered a rather 33 uncomplicated matter due to the effectiveness of various antibiotics. Fortunately that still applies, 34 although the treatment of some bacterial infections has become gradually more complicated in recent 35 years because of the increase in bacterial resistance against conventional antibiotics. This is made 36 obvious by the fact that infectious diseases are the third leading cause of death in developed countries, 37 despite the abundant availability of antibiotics 1 .
38
The emergence of bacteria with resistance towards conventional antibiotics is increasing at an alarming illustrates a development that calls for concern 2, 4 . In that perspective, it is important to pursue the 47 development of new antimicrobial agents, with a novel mode of action, to ensure that we will be able to biological effect is reflected in the characteristics of antimicrobial peptides having a great deal of 57 diversity, in both primary and secondary structure, probably explaining their evolutionary success 7 .
58
Even so, there are a number of structural similarities that apply for most antimicrobial peptides, usually 59 4 being relatively short, ranging from 12-50 amino acids, carrying a net positive charge of +2 to +9 and 60 having a distinct proportion of hydrophobic residues 8 .
61
The positive charge of antimicrobial peptides is generally accepted as the main feature that mediates 
Material and methods
88
Solid phase peptide synthesis 89 The peptides were synthesized using solid phase Fmoc chemistry with amidation on the carboxyl end,
90
purified by reverse-phase HPLC using a C 18 column (Higgins Analytical Inc. 10 µm 250x10 mm) and a
91
water/acetonitile gradient. The correct mass and purity >95% was verified using Dionex Ultimate 3000
92
RP-UHPLC (C18 Kinetex 100 x 2.1 mm, 100 Å) electrospray ionization mass spectrometry (Finnigan 93 LTQ) ( Figure S1 , Table S1 ).
95
Minimal inhibitory concentration determination
96
The antimicrobial efficacy of peptides was tested using a serial dilution titration, as previously Hinton broth and re-grown to mid-log phase before diluting to a turbidity of OD 600 0.1. A microtiter 
159
The effect on both bacterial DNA content and change in cell size after exposure with peptides was 
Results
245
This study aimed at characterizing the bacterial inhibition and antibacterial mode of action of a set of 246 highly active antimicrobial peptides earlier identified by Fjell et al. 12 . antimicrobial activity against S. aureus was observed for GN-5 peptide (1.5 µg/mL), and GN-2 and 254 GN-6 peptides (3.1 µg/mL). However, in respect to a broad spectrum antimicrobial potential, peptide
255
GN-2 and GN-4 appear as best candidates.
256
In an attempt to explain the antibacterial peptide properties with classical chemical properties the Table 1) . In order to further characterize the antimicrobial profiles of the GN peptides, their 260 ability to selectively target bacterial-versus mammalian cells was assessed using hemolytic assay.
261
Human red blood cells were exposed to different concentrations of GN peptides and the degree of lysis 262 was evaluated. All peptides resulted in a dose dependent release of hemoglobin, and toxicity is reported structurally differs from GN-2 peptide in the presence of phenylalanine and a patch of 4 consecutive 280 tryptophan residues was also considered for characterization for the mechanism of bacterial inhibition.
281
First to differentiate between bactericidal or bacteriostatic mode of antibacterial activity, colony 282 forming unit counts were monitored for E. coli cultures exposed to 1×, 2×, and 4×MIC concentrations 
355
Only a small concentration change from 3.5 µg/mL to 5.5 µg/mL of GN-2, changes the calcein release 356 from about 30% to 100%. Conversely, the GN-6 peptide, which has slightly lower antimicrobial the GN peptides -8, -9, -11 and -14 which have either leucine or isoleucine in addition to one cationic
396
(either lysine or arginine) and one tryptophan residues within their structure and exhibit lower 397 antimicrobial activities.
398
To understand the overall activity of the GN peptides and their ability to selectively discriminate 399 between bacterial and mammalian membranes, and therefore obtain a selectivity index as a ranking tool ascribed as a contributor to the higher lytic effects 21 , exerts the same effect when compared to arginine 408 in GN-2 peptide ( Table 1) .
For a better differentiation of host cell toxicity, metabolic activities in HeLa cells were also monitored.
410
Comparing toxicity against HeLa cells with the hemolytic properties of the GN peptides, reveals a 411 disproportionally high toxicity towards the former ( employed.
418
The current study demonstrate a fast decrease of exponentially growing E. coli when exposed to sub-
419
MIC concentrations of both peptide GN-2 and GN-6 (Figure 1 and 2) . The observed decrease is 420 probably due to metabolic disturbance that halts bacterial growth for about 80 minutes, after which the 421 growth is reestablished. This is also in agreement with the OD measurements, which revealed similar 
444
The later mechanism would require presence of ATP for efflux pumps which could be in agreement by others been demonstrated to work through this mechanism 36 .
468
Previous studies have shown that melittin is a pore forming membrane active peptide that acts in an all 469 or none manner 19c, 37 , resulting in these immediate release profiles of calcein. Since the current study 470 showed similar kinetics in mediating calcein release for both melittin and GN-2, it is reasonable to 471 assume that the GN-2 peptide also acts by pore formation mechanism. However the calcein release for 472 mellitin is much more pronounced at lower concentrations when compared to the release for peptide 
484
In conclusion, based on the experimental data obtained in the current study the primary antibacterial 485 mechanism of action of GN-2 and GN-6 is associated with membrane permeabilization at high peptide Figure 1 . Viability of exponentially growing E. coli ATCC 25922 exposed to 1x, 2x, and 4x MIC concentrations of (A) GN-2 peptide and (B) GN-6 peptide over a course of 3 hours. Data represent mean and SEM of 3 independent experiments. 97x148mm (600 x 600 DPI) Figure 2 . Optical density measurements of exponentially growing E. coli ATCC 25922 over 5 hours. Data presents mean of 3 independent experiments based. Bacterial growth at 37°C in a 96-well plates from a starting inoculum of OD600 of 0.1 has been measured with 8 minutes intervals. (A) Bacteria exposed to antibiotics at MIC concentrations, Ampicillin (4 µg/ml), Tobramycin (0.78 µg/ml), Tetracycline (1 µg/ml) and Ciprofloxacin (0.05 µg/ml). (B) Bacteria exposed to GN-2 peptide at 1x MIC (6.2 µg/ml) and 2x MIC (12.5 µg/ml) and GN-6 peptide at 1x MIC (12.5 µg/ml) and 2x MIC (25 µg/ml) concentrations. 42x12mm (600 x 600 DPI) (A) Bacteria exposed to antibiotics at MIC concentrations, Ampicillin (4 µg/ml), Tobramycin (0.78 µg/ml), Tetracycline (1 µg/ml) and Ciprofloxacin (0.05 µg/ml). (B) Bacteria exposed to GN-2 peptide at 1x MIC (6.2 µg/ml) and 2x MIC (12.5 µg/ml) and GN-6 peptide at 1x MIC (12.5 µg/ml) and 2x MIC (25 µg/ml) concentrations. 
